The use of GPCR structures in drug design.

Structure-based drug discovery is routinely applied to soluble targets such as proteases and kinases. It is only recently that multiple high-resolution X-ray structures of G protein-coupled receptors (GPCRs) have become available. Here we review the technology developments that have led to the recent plethora of GPCR structures. These include developments in protein expression and purification as well as techniques to stabilize receptors and crystallize them. We discuss the findings derived from the new structures with regard to understanding GPCR function and pharmacology. Finally, we examine the utility of structure-based drug discovery approaches including homology modeling, virtual screening, and fragment screening for GPCRs in the context of what has been learnt from other target classes.

[1]  M. Maccoss,et al.  Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.

[2]  Bartosz Trzaskowski,et al.  Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. , 2010, Journal of structural biology.

[3]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[4]  Gebhard F. X. Schertler,et al.  The structural basis of agonist-induced activation in constitutively active rhodopsin , 2011, Nature.

[5]  A. Cashen Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. , 2009, Drugs of today.

[6]  Christoph Seibert,et al.  Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.

[7]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[8]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[9]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[10]  M. Sabio,et al.  Exploration of structure-based drug design opportunities for mGluRs , 2011, Neuropharmacology.

[11]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[12]  T. Werge Identification of an epitope in the substance P receptor important for recognition of the common carboxyl-terminal tachykinin sequence. , 1994, The Journal of biological chemistry.

[13]  F. Petitet,et al.  Knowledge-based analysis of multi-potent G-protein coupled receptors ligands. , 2010, European journal of medicinal chemistry.

[14]  B Clotet,et al.  Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. , 1999, Molecular pharmacology.

[15]  H. Xu,et al.  Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.

[16]  H. Senderowitz,et al.  G protein coupled receptors -in silico drug discovery and design. , 2010, Current topics in medicinal chemistry.

[17]  H. Senderowitz,et al.  G Protein-Coupled Receptors: target-based in silico screening. , 2009, Current pharmaceutical design.

[18]  R. Grisshammer,et al.  Purification and characterization of the human adenosine A2a receptor functionally expressed in Escherichia coli , 2002 .

[19]  J. Rubin,et al.  Chemokine signaling in cancer: one hump or two? , 2009, Seminars in cancer biology.

[20]  M. Brann,et al.  The Second Intracellular Loop of the m5 Muscarinic Receptor Is the Switch Which Enables G-protein Coupling* , 1998, The Journal of Biological Chemistry.

[21]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Andreas Plückthun,et al.  Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity , 2008, Proceedings of the National Academy of Sciences.

[23]  J. Holst,et al.  Treatment of type 2 diabetes with glucagon‐like peptide‐1 receptor agonists , 2009, International journal of clinical practice.

[24]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[25]  Claudio N. Cavasotto,et al.  Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.

[26]  Leonardo Pardo,et al.  Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. , 2007, Current topics in medicinal chemistry.

[27]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[28]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[29]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[30]  Philip J. Reeves,et al.  Structure and function in rhodopsin: A tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Arthur Christopoulos,et al.  A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.

[32]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[33]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[34]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[35]  S. Charlton,et al.  A common intracellular allosteric binding site for antagonists of the CXCR2 receptor , 2010, British journal of pharmacology.

[36]  F. Marshall,et al.  RAMPs: accessory proteins for seven transmembrane domain receptors. , 1999, Trends in pharmacological sciences.

[37]  Christopher G. Tate,et al.  The structural basis for agonist and partial agonist action on a β1-adrenergic receptor , 2010, Nature.

[38]  Maria A Miteva,et al.  Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.

[39]  F. Blaney,et al.  GPCR Homology Model Development and Application , 2010 .

[40]  D. Nicholls,et al.  Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.

[41]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[42]  S. Hoare,et al.  Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.

[43]  H. Kikkawa,et al.  The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.

[44]  W. Goddard,et al.  Computational modeling of structure-function of g protein-coupled receptors with applications for drug design. , 2010, Current medicinal chemistry.

[45]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[46]  Anat Levit,et al.  Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. , 2010, Current opinion in drug discovery & development.

[47]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[48]  Andreas Evers,et al.  Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.

[49]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[50]  W. Weis,et al.  Structural insights into G-protein-coupled receptor activation. , 2008, Current opinion in structural biology.

[51]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[52]  R. Rudolph,et al.  Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.

[53]  Prashant V Desai,et al.  Homology modeling of G-protein-coupled receptors and implications in drug design. , 2006, Current medicinal chemistry.

[54]  Sid Topiol,et al.  X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.

[55]  B. Kobilka,et al.  New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.

[56]  A. IJzerman,et al.  The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. , 2010, Current opinion in structural biology.

[57]  B. Sykes,et al.  Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.

[58]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[59]  Nobuhiro Yamamoto,et al.  Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6. , 2009, Bioorganic & medicinal chemistry letters.

[60]  Stefano Costanzi,et al.  Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.

[61]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[62]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[63]  R. Hodgson,et al.  Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. , 2010, Current opinion in drug discovery & development.

[64]  A. Gilchrist GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions , 2010 .

[65]  R. Horuk,et al.  I want a new drug: G-protein-coupled receptors in drug development. , 2006, Drug discovery today.

[66]  Donald J. Abraham,et al.  Burger's medicinal chemistry, drug discovery, and development , 2010 .

[67]  Thomas M Frimurer,et al.  Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.

[68]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[69]  G. Marucci,et al.  Adenosine receptor modeling: what does the A2A crystal structure tell us? , 2010, Current topics in medicinal chemistry.

[70]  Yoko Shibata,et al.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.

[71]  Jian Cai,et al.  Expression of CB2 cannabinoid receptor in Pichia pastoris. , 2002, Protein expression and purification.

[72]  M. Hauser,et al.  Unnatural amino acid replacement in a yeast G protein-coupled receptor in its native environment. , 2008, Biochemistry.

[73]  R. Duckworth,et al.  Expression of a rat neurotensin receptor in Escherichia coli. , 1993, The Biochemical journal.

[74]  Stefano Costanzi,et al.  A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.

[75]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[76]  Frank E. Blaney,et al.  4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling , 2007 .

[77]  Santosh A. Khedkar,et al.  Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. , 2010, Current topics in medicinal chemistry.

[78]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[79]  K. Wreggett,et al.  An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5 , 2008, Molecular Pharmacology.

[80]  Yoko Shibata,et al.  Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.

[81]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[82]  Sebastian Radestock,et al.  Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..

[83]  N. Blomberg,et al.  An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.

[84]  C. Tate Practical considerations of membrane protein instability during purification and crystallisation. , 2010, Methods in molecular biology.

[85]  K. Kameyama,et al.  Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. , 1991, The Journal of biological chemistry.

[86]  H. Xu,et al.  Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.

[87]  Wolfgang Guba,et al.  Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. , 2007, Journal of medicinal chemistry.

[88]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[89]  Yoko Shibata,et al.  Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.

[90]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[91]  C. Hunte,et al.  Specific protein-lipid interactions in membrane proteins. , 2005, Biochemical Society transactions.

[92]  C. Koth,et al.  Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.

[93]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[94]  P. Portoghese Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. , 1989, Trends in pharmacological sciences.

[95]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[96]  Ruben Abagyan,et al.  GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2a receptor complex , 2010, Proteins.

[97]  Kenneth A Jacobson,et al.  Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. , 2003, Journal of medicinal chemistry.

[98]  M. Caffrey Crystallizing membrane proteins for structure determination: use of lipidic mesophases. , 2009, Annual review of biophysics.

[99]  Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. , 1997, Molecular endocrinology.

[100]  B. Druker,et al.  Imatinib as a paradigm of targeted therapies. , 2004, Advances in cancer research.

[101]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[102]  Ian T. Crosby,et al.  Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[103]  P. Goadsby,et al.  CGRP and its receptors provide new insights into migraine pathophysiology , 2010, Nature Reviews Neurology.

[104]  J. Trujillo-Ferrara,et al.  Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist. , 2009, European journal of medicinal chemistry.

[105]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[106]  Steven O. Smith Structure and activation of the visual pigment rhodopsin. , 2010, Annual review of biophysics.

[107]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.

[108]  Marta Filizola,et al.  Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.

[109]  S. Rasmussen,et al.  A monoclonal antibody for G protein–coupled receptor crystallography , 2007, Nature Methods.

[110]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[111]  J. Popot,et al.  Amphipol-assisted in vitro folding of G protein-coupled receptors. , 2009, Biochemistry.

[112]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[113]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[114]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[115]  S. Moro,et al.  Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. , 2010, Bioorganic & medicinal chemistry.

[116]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[117]  Markus G Grütter,et al.  Opportunities for structure-based design of protease-directed drugs. , 2006, Current opinion in structural biology.

[118]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[119]  Hideo Takahashi,et al.  Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.

[120]  Giuseppe Nano,et al.  2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. , 2005, Journal of medicinal chemistry.

[121]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.